1. Introduction {#sec1-cancers-10-00442}
===============

Ovarian carcinoma (OC), one of the most common gynecological malignancies, accounts for an estimated 239,000 new cases and 152,000 deaths worldwide annually, with the highest incidence rate in Central and Eastern Europe (11.4 per 100,000) \[[@B1-cancers-10-00442]\]. Although the 5-year relative survival rate for all stages combined increased from 33.7% in 1975 to almost 50% in 2009 \[[@B2-cancers-10-00442]\], OC is still the leading cause of death from cancer in women. Because of non-specific symptoms and the lack of effective screening tests, most individuals are diagnosed with an advanced disease (stage III or IV) with the 5-year survival rate below 30% \[[@B3-cancers-10-00442]\].

Morphologically, the epithelial neoplasms are divided into five main subtypes (serous, endometrial, mucinous, clear cell and transitional cell tumors) that have different genetic risk factors, treatment responses, and prognosis. High-grade serous ovarian carcinoma represents approximately 70% of OC, followed by endometrial and clear cell cancer (10% each) \[[@B4-cancers-10-00442]\]. The first-line treatment includes optimal cytoreductive surgery and platinum-based chemotherapy; however, chemotherapy sensitivity varies widely among individuals, depending mostly on the tumor's histologic subtype with its grade, as well as the overall cancer stage \[[@B5-cancers-10-00442],[@B6-cancers-10-00442]\].

Since the identification of tumor suppressor genes, *BRCA1* and *BRCA2* \[[@B7-cancers-10-00442],[@B8-cancers-10-00442]\], of which germline pathogenic variants predispose to a significant increase in breast and ovarian cancer risk, several other cancer-related genes have been associated with their pathogenesis and progression. The application of next-generation sequencing (NGS) significantly facilitates rapid screening for new cancer susceptibility genes, and indeed, a number of pathogenic variants in the so-called moderate- and low-penetrance genes, such as *ATM*, *BRIP1*, *CHEK2*, *PALB2* or *BARD1*, have been reported to be correlated with a moderate lifetime risk for breast and/or ovarian cancer \[[@B9-cancers-10-00442]\]. However, so far for OC, these data are still limited, and only the loss-of-function pathogenic variants of the mismatch repair (MMR) genes, that is, *MLH1*, *MSH2*, *MSH6,* and *PMS2*, are clearly classified as OC-susceptibility genes \[[@B10-cancers-10-00442]\].

In this study, we established the prevalence and spectrum of the constitutional pathogenic variants in the *BRCA1/2* and 23 other cancer-related genes that may play a role in the predisposition to OC, in a large Polish population of 333 unselected OC individuals.

2. Results {#sec2-cancers-10-00442}
==========

2.1. Pathogenic Variants in BRCA1/2 {#sec2dot1-cancers-10-00442}
-----------------------------------

All individuals included in this study had the comprehensive *BRCA1*/*2* molecular screening as a part of our previous study \[[@B11-cancers-10-00442]\]. In total, pathogenic variants were found in 71 cases (*n* = 71/333; 21.3%), with the vast majority of variants located in *BRCA1* (*n* = 60/71; 84.5%), and only eleven in *BRCA2* (15.5%). Forty individuals (*n* = 40/71; 56.3%) were heterozygous for one of the most recurrent pathogenic variants observed in the Polish population, i.e., c.68_69del (p.Glu23Valfs\*17), c.181T\>G (p.Cys61Gly), c.3700_3704del (p.Val1234Glnfs\*8), c.4035del (p.(Glu1346Lysfs\*20) and c.5266dup (p.Gln1756Profs\*74), all located in *BRCA1* \[[@B12-cancers-10-00442],[@B13-cancers-10-00442],[@B14-cancers-10-00442]\]. The most common pathogenic variants were c.5266dup (p.Gln1756Profs\*74) and c.3700_3704del (p.Val1234Glnfs\*8), accounting for 31% (*n* = 22/71) and 21.1% of cases (*n* = 15/71), respectively.

Among *BRCA1/2* positive cases, the most common histological subtype was serous OC (*n* = 59/71; 83.1%), followed by low differentiated (*n* = 5/71; 7%) and endometrial (*n* = 3/71; 4.2%) tumors. Clear cell and mesonephroid tumors each were represented in less than 3% (*n* = 2/71; 2.8%) of positive cases.

The average age of onset in *BRCA1*/*2* carriers was 58.2 years (range: 27--87), with ten years of difference in diagnosis between *BRCA1* and *BRCA2* individuals (49.3 versus 59 years). All pathogenic variants identified in the *BRCA1* and *BRCA2* genes are displayed in [Table 1](#cancers-10-00442-t001){ref-type="table"} and [Figure 1](#cancers-10-00442-f001){ref-type="fig"}.

2.2. Pathogenic Variants in Moderate- and Low-Penetrance Genes {#sec2dot2-cancers-10-00442}
--------------------------------------------------------------

To further characterize this cohort, we analyzed 23 additional genes that might play a role in the predisposition to OC. Briefly, we identified 6% of carriers (*n* = 20/333) with 16 different pathogenic variants in one of the tested genes. The most frequently mutated genes were *NBN* and *CHEK2*, with pathogenic or likely pathogenic variants presented in six (*n* = 6/20; 30%) and four individuals (*n* = 4/20; 20%), respectively. Among six cases with the *NBN* pathogenic or likely pathogenic variants, four carried a well-known founder mutation, c.657_661del (p.Lys219Asnfs\*16). In addition, we found two different pathogenic variants in the *BLM* and *PALB2* genes, and in *APC*, *ATM*, *BRIP1*, *MRE11A*, *RAD50*, *RAD51C* (each variant observed in a single individual). Additionally, within this cohort, four cases were also carriers of the *BRCA1* pathogenic variants (see details in [Table 2](#cancers-10-00442-t002){ref-type="table"}).

The average age of onset in this group of individuals was 53.9 (range 27--76). All identified variants that were classified as potentially causative (pathogenic or likely pathogenic) are displayed in [Table 2](#cancers-10-00442-t002){ref-type="table"} and [Figure 2](#cancers-10-00442-f002){ref-type="fig"}.

2.3. Variants of Uncertain Significance (VUS) in Low-Penetrance Genes {#sec2dot3-cancers-10-00442}
---------------------------------------------------------------------

Detailed list of all identified VUS is shown in [Table S1](#app1-cancers-10-00442){ref-type="app"}. The most common alteration was a missense variant in *CHEK2*, c.470T\>C (p.Ile157Thr), with a prevalence of 2.7% (*n* = 9/333), including two individuals being recognized as carriers of the *BRCA1* pathogenic variants. The second most frequently observed variant was c.511A\>G (p.Ile171Val) in the *NBN* gene, found in six individuals (*n* = 6/333; 1.8%), including two carriers of *BRCA1* and *PALB2* pathogenic variants. Additionally, in two patients, we identified two different variants located in consensus splice site region (c.38-3C\>G and c.30G\>A) of the *NBN* gene, resulting possibly in an abnormal splicing. However, as no source of RNA was available for these individuals, the missplicing cannot be confirmed.

Finally, we identified an individual classified as a compound heterozygous for *BARD1*, with an in-frame deletion in exon 4, c.1075_1095del (p.Leu359_Pro365del), and a silent mutation c.1977A\>G, both variants reside in the *trans* position. The proband, diagnosed with OC at the age of 65, had a positive family history for this type of cancer. The proband's sister died of OC at the age of 36 over three decades ago; therefore, no biological material was available to perform further genetic testing ([Figures S1 and S2](#app1-cancers-10-00442){ref-type="app"}).

3. Discussion {#sec3-cancers-10-00442}
=============

Constitutional loss-of-function pathogenic variants in the tumor suppressor genes *BRCA1* and *BRCA2* are widely known to confer an elevated risk of breast and/or ovarian cancer, and their mutational screening has become a standard in routine diagnostic practice. It has been estimated that the lifetime risk for developing OC varies from 20% to 50%, depending on the gene in which the pathogenic variant occurs \[[@B17-cancers-10-00442]\]. As only \~15% of OC individuals are heterozygous for the *BRCA1/2* pathogenic variants \[[@B18-cancers-10-00442],[@B19-cancers-10-00442],[@B20-cancers-10-00442]\], the identification of other genes associated with inherited susceptibility to OC is of great clinical importance. So far, several studies aimed at the evaluation of germline alterations in other genes using multi-gene panel testing in a large series of well-characterized OC individuals have been performed, and the potential moderate- and low-penetrance genes have been reported, but their elevated risk of OC is less well characterized \[[@B9-cancers-10-00442],[@B10-cancers-10-00442],[@B21-cancers-10-00442],[@B22-cancers-10-00442],[@B23-cancers-10-00442]\]. Importantly, considering the ethnicity-specific differences in the variants spectrum and frequency, their assessment in all ethnic groups, including the Polish population, is required before making any clinical conclusions. Therefore, in this report, we investigated the prevalence and spectrum of the germline pathogenic and likely pathogenic variants in 25 cancer-related genes through a comprehensive NGS analysis in a large cohort of 333 unselected OC individuals from northern Poland.

Overall, we identified 91 pathogenic or likely pathogenic variant in 87 OC individuals (*n* = 87/333; 26.1%;) ([Figure 3](#cancers-10-00442-f003){ref-type="fig"}), in agreement with the previous reports \[[@B23-cancers-10-00442],[@B24-cancers-10-00442],[@B25-cancers-10-00442]\]. Besides the *BRCA1/2* genes, the most frequently mutated were *NBN* and *CHEK2,* with the alterations observed in 1.8% (*n* = 6/333) and 1.2% (*n* = 4/333) of cases, respectively ([Table 2](#cancers-10-00442-t002){ref-type="table"}). Both genes encode for proteins involved in nonhomologous end joining (NHEJ) or homologous recombination (HR), which are critical mechanisms for the accurate repair of DNA double-strand breaks (DSBs). Particularly, nibrin, the product of the *NBN* gene, regulates the activity of the MRE11A/RAD50/NBN protein complex, while checkpoint kinase 2, the product of the *CHEK2* gene, is activated upon DNA damage, and is responsible for transducing the DNA damage signal to downstream repair proteins, such as p53 \[[@B21-cancers-10-00442]\]. According to the recent National Comprehensive Cancer Network (NCCN) guidelines, germline pathogenic variants in both these genes confer to an elevated risk of breast cancer, with the recommendation of the annual mammogram beginning at the age of 40; for OC individuals, however, these variants are not proven to result in an increased risk of OC, or rather, insufficient evidence have been so far reported \[[@B26-cancers-10-00442]\]. In line with the previous studies, suggesting that the specific *CHEK2* variant c.1100del (p.Thr367Metfs\*15) is more prevalent in the Northern and Eastern Europe countries compared with North America \[[@B27-cancers-10-00442],[@B28-cancers-10-00442]\], we identified the presence of this alteration in two cases from the studied cohort ([Table 2](#cancers-10-00442-t002){ref-type="table"} and [Figure 2](#cancers-10-00442-f002){ref-type="fig"}). However, both individuals carried simultaneously a pathogenic variant in the *BRCA1* gene; therefore, our findings likely confirmed the previous observations indicating a lack of c.1100del association with an increased risk of OC \[[@B29-cancers-10-00442]\]. Regarding the *NBN* gene, several studies clearly shown the elevated risk of breast cancer with a positive *NBN* testing result, however, this risk assessment was limited to a specific *NBN* pathogenic variant, c.657_661del (p.Lys219Asnfs\*16), observed frequently in the Slavic population \[[@B30-cancers-10-00442],[@B31-cancers-10-00442]\]. In this report, variant c.657_661del was present in 4/6 *NBN* mutation-positive individuals ([Table 2](#cancers-10-00442-t002){ref-type="table"} and [Figure 2](#cancers-10-00442-f002){ref-type="fig"}). Other potentially causative variants in the *NBN* gene included novel nonsense and missense alterations, c.373A\>T (p.Lys125\*) and c.643C\>T (p.Arg215Trp), respectively; the remaining was previously described in twin brothers with Nijmegen breakage syndrome (MIM: 251260) \[[@B32-cancers-10-00442]\]. All but one individual with a positive *NBN* screening result had a negative family history for cancer, with the negative result of the *BRCA1/2* screening. As there is clear evidence that alterations in this gene predispose to an increased risk of breast cancer, but for determining the risk assessment for OC further studies are required, the clinicians involved in the case of OC individuals should be aware of this potential association.

Several other proteins, coded by one of the following genes: *ATM*, *BLM*, *BRIP1*, *MRE11A*, *PALB2*, *RAD50* or *RAD51C*, interact with BRCA1/2 proteins in the DBs repair process by HR or NHEJ mechanism, and therefore, they are considered as alternative candidates for OC-susceptibility genes. Indeed, it has been reported that the *BRIP1* and *RAD51* pathogenic variants confer at least a 6-fold increased risk for OC \[[@B29-cancers-10-00442],[@B33-cancers-10-00442],[@B34-cancers-10-00442]\], but not for breast cancer, in contrast to the *NBN* and *CHEK2* genes. Although the pathogenic variants in these genes were identified in the current study only in two cases (each in a single individual), from a clinical point of view, these results had a great impact on the management of these individuals, as they should be offered risk-reducing salpingo-oophorectomy (RRSO) at the age of 45--50, in line with the current NCCN recommendations \[[@B26-cancers-10-00442]\]. We also found the pathogenic or likely pathogenic variants in other genes, such as *ATM*, *BLM*, *MRE11A*, *PALB2,* or *RAD50*, occurring sporadically in 1--2 individuals ([Table 2](#cancers-10-00442-t002){ref-type="table"}), but their role in the predisposition to OC is still unclear \[[@B29-cancers-10-00442],[@B35-cancers-10-00442],[@B36-cancers-10-00442],[@B37-cancers-10-00442]\].

The most striking finding was the paucity of the pathogenic variants in any of the MMR genes, resulting in Lynch syndrome (MIM: 120435), that is, *MLH1*, *MSH2*, *MSH6,* or *PMS2*, that are clearly considered as the major causes of hereditary epithelial OC in addition to *BRCA1/2* alterations, with a lifetime risk of OC estimated at 6--10% \[[@B10-cancers-10-00442]\]. One of the possible explanations might be that OC in Lynch syndrome is mostly of endometrial or clear cell histology \[[@B29-cancers-10-00442],[@B38-cancers-10-00442],[@B39-cancers-10-00442]\], while \~70% of cases in the studied cohort represent the high-grade serous OC subtype. Nevertheless, similar to the *BRIP1* and *RAD51* pathogenic variants carriers, individuals heterozygous for a pathogenic variant within one of the aforementioned MMR genes may consider prophylactic RRSO and/or total abdominal hysterectomy \[[@B26-cancers-10-00442]\]; thus, it is critical to identify early those women to provide them with accurate genetic counseling and personalized surveillance.

In the current study, the pathogenic and likely pathogenic variants in the *BRCA1/2* genes were identified in 18% (*n* = 60/333) and 3.3% (*n* = 11/333) of cases for *BRCA1* and *BRCA2*, respectively, together affecting \~21% of women ([Table 1](#cancers-10-00442-t001){ref-type="table"} and [Figure 1](#cancers-10-00442-f001){ref-type="fig"}) who are eligible for the poly (ADP-ribose) polymerase 1 inhibitors (iPARP1) -targeted therapy \[[@B40-cancers-10-00442]\]. Comparing with our preliminary data reported on 134 OC individuals with 20 *BRCA1/2* mutation-positive carriers \[[@B11-cancers-10-00442]\], the prevalence here was higher than previously observed (21% versus 14.9%); however, this is still in line with the recent large-scale study performed on 21,401 families, with the *BRCA1/2* overall frequency of 24% \[[@B41-cancers-10-00442]\]. As expected, the most recurrent pathogenic variants were Polish founder mutations, that is, c.5266dup (p.Gln1756Profs\*74) and c.3700_3704del (p.Val1234Glnfs\*8), accounting for 6.6% (*n* = 22/333) and 4.5% of all cases (*n* = 15/333), respectively. Indeed, Rebbeck et al. (2018) clearly confirmed based on the analysis performed on 29,700 *BRCA1/2*-mutation positive families that these two alterations are the most commonly-observed variants in Eastern Europe, including Polish population \[[@B19-cancers-10-00442]\].

The natural consequence of comprehensive molecular screening is a growing number of VUS, for which interpretation is often challenging and clinically problematic. In the present study, we described an individual being a compound heterozygous for *BARD1*, with an in-frame deletion in exon 4, c.1075_1095del (p.Leu359_Pro365del), and a silent mutation c.1977A\>G, reside in *trans* position ([Figures S1 and S2](#app1-cancers-10-00442){ref-type="app"}). Both alterations lead to missplicing and overexpression of alternative isoforms, named *gamma* and *eta*, and consequently, to significant telomere instability \[[@B42-cancers-10-00442]\]. Taking into account a positive family history for OC, potential actionability of those variants cannot be excluded.

A considerable percentage of mutation-positive individuals for whom the personal data was available was diagnosed at the age of ≥60 (*n* = 18/85; 21%). Numerous carriers presented a negative family history for cancer, confirming prior observations of the limited significance of age on onset and family history when selecting patients for genetic screening ([Table 1](#cancers-10-00442-t001){ref-type="table"} and [Table 2](#cancers-10-00442-t002){ref-type="table"} and [Figure 3](#cancers-10-00442-f003){ref-type="fig"}B,C) \[[@B11-cancers-10-00442],[@B20-cancers-10-00442],[@B43-cancers-10-00442]\].

In conclusion, we reported here the spectrum and prevalence of the pathogenic and likely pathogenic variants in OC-susceptibility genes in a Polish population. Through a comprehensive NGS analysis of the high-penetrance *BRCA1/2* genes and 23 additional moderate- and low-penetrance genes in a large cohort of 333 unselected OC women from northern Poland, we estimated the overall ethnicity-specific pathogenic variants' frequency in these genes at \~26%, including \~21% of the *BRCA1/2* mutation-positive individuals and \~5% of cases with pathogenic alterations in the other cancer-related genes.

Although the mutational screening using multi-gene panel testing have not yet had therapeutic implications, as only the individuals confirmed with an advanced high-grade serous OC and heterozygous for the germline or somatic *BRCA1/2* pathogenic variant are eligible for the targeted therapy with iPARP1 (The Polish National Health Program), the identification of the alterations in other OC-susceptibility genes may significantly improve the personalized risk assessment for OC in these individuals. Patients with *RAD51C* and *RAD51D* pathogenic variants who were enrolled in the ARIEL 3 trial showed a significant response to the treatment, with an average progression-free survival time (PFS) of 16.4 months (range, 5.4--30.4 months) \[[@B25-cancers-10-00442]\]. In addition, reversion mutations leading to regained function of HR-proteins (e.g., BRCA1, RAD51C and RAD51D) in tumor cells result in PARP resistance \[[@B44-cancers-10-00442]\]. These results indicate that the target group of OC patients that may benefit from iPARP therapy is more heterogeneous, and as a consequence, that targeted therapies programs inclusion criteria should be amended accordingly.

The application of this approach will allow early detection in those women with pathogenic variants in the genes that clearly predispose them to an elevated risk of OC, providing them accurate genetic counseling with prophylactic management options. Finally, as several of these OC-susceptibility genes, i.e., *NBN, ATM* or *BRIP1*, are associated with the development of autosomal recessive disorders, such as Nijmegen breakage syndrome, ataxia-teleangiectasia (MIM: 208900) or Fanconi anemia (MIM: 609054), respectively, genetic counselling for carriers of pathogenic variants in any of these genes should also include a discussion of reproductive and prenatal screening possibilities.

4. Materials and Methods {#sec4-cancers-10-00442}
========================

4.1. Individuals and Sample Collection {#sec4dot1-cancers-10-00442}
--------------------------------------

The study comprised 333 unselected for age or family history ovarian cancer individuals that were referred to the University Hospital in Gdansk and the Red Cross Hospital in Gdynia between 2007 and 2013.

The histological diagnosis of ovarian cancer was evaluated by an expert pathologist; the most representative subtypes were as follows: serous ovarian cancer, accounting for 70.3% (*n* = 234/333) of cases, followed by endometrial (*n* = 32/333; 9.6%;), mucinous (*n* = 18/333; 5.4%;), undifferentiated (*n* = 18/333; 5.4%;), and clear cell subtype (*n* = 13/333; 3.9%;). The remaining 22 cases included tumors of mixed type (*n* = 8), unspecified tumors (*n* = 5), carcinosarcomas (*n* = 3), *leiomyosarcomas, and adult granulosa* cell tumors (each observed in a single individual). The average age at diagnosis was 58.6 years (27--87).

Informed consent was obtained from all the individuals and the study was approved by the medical review board of the Medical University of Gdansk (NKEBN/399/2011-2012; NKBBN/446/2015).

4.2. DNA Extraction {#sec4dot2-cancers-10-00442}
-------------------

Genomic DNA was extracted from the whole blood using a red-blood-cell lysis buffer followed by standard phenol-chloroform procedure.

4.3. Molecular Analysis {#sec4dot3-cancers-10-00442}
-----------------------

All samples enrolled to the study were screened for *BRCA1* (MIM: 113705) and *BRCA2* (MIM: 600185) pathogenic variants using NGS with *BRCA* MASTR assay v1.2 (Multiplicom, Niel, Belgium). Molecular analysis of additional 23 genes, including *APC* (MIM: 611731), *ATM* (MIM: 607585), *BARD1* (MIM: 601593), *BLM* (MIM: 604610), *BRIP1* (MIM: 605882), *CDH1* (MIM: 192090), *CDKN2A* (MIM: 600160), *CHEK2* (MIM: 604373), *MLH1* (MIM: 120436), *MRE11A* (MIM: 600814), *MSH2* (MIM: 609309), *MSH6* (MIM: 600678), *NBN* (MIM: 602667), *PALB2* (MIM: 610355), *PMS2* (MIM: 600259), *PTEN* (MIM: 601728), *RAD50* (MIM: 604040), *RAD51* (MIM: 179617), *RAD51B* (MIM: 602948), *RAD51C* (MIM: 602774), *RAD51D* (MIM: 602954), *STK11* (MIM: 602216), *TP53* (MIM: 191170), was performed using a combination of TruSeq Custom Amplicon assay (Illumina Inc., San Diego, CA, USA) and the HEAT-Seq Oncology Panel (Roche Sequencing), followed by MiSeq targeted re-sequencing at minimum of 99× coverage (Illumina, Inc., San Diego, CA, USA). The cut-off of 20% was applied. The analysis was performed with Illumina Variant Studio Software v3.0 (Illumina Inc., San Diego, CA, USA), Sequence Pilot (JSI Medical Systems, Ettenheim, Germany) and Geneious Software v9.05 (Biomatters Ltd., Auckland, New Zealand). Presence of pathogenic or likely pathogenic variants detected by NGS analysis was confirmed by bi-directional Sanger Sequencing (ABI PRISM 3130, Life Technologies, Inc., Carlsbad, CA, USA). Interpretation of variants pathogenicity was performed based on the American College of Medical Genetics and Genomics (ACMG) recommendations \[[@B15-cancers-10-00442]\].

5. Conclusions {#sec5-cancers-10-00442}
==============

In conclusion, we propose obligatory *BRCA1/2* screening in all OC patients in the Polish population. In addition, in the negative cases analysis of the additional cancer-related genes should be considered, including MMR genes, *BRIP1*, *RAD51C*, and *RAD51D*. Unfortunately, given the potential costs of such expanded diagnostics, it will probably need to be limited to the selected group of patients with specific clinical and histopathological characterization.

To establish recommendations for the expansion of mutational analysis (including other cancer-related genes) in OC-individuals, further studies in larger OC series with detailed family histories are required.

We thank the individuals and their families for participating in this study. Magdalena Koczkowska, PhD is also affiliated with the Department of Genetics, University of Alabama at Birmingham, AL, USA.

The following are available online at <http://www.mdpi.com/2072-6694/10/11/442/s1>. Figure S1: A pedigree of the family with proband being a compound heterozygote for two *BARD1* variants: an in-frame deletion in exon 4, c.1075_1095del (p.Leu359_Pro365del) and a silent variant in exon 10, c.1977A\>G, resulting in the missplicing, \[r.159\\\_1903del\], \[=\] (p.Cys53_Trp635delinsfs\*12); Figure S2: Extended analysis result for variants: c.1075_1095del and c.1977A\>G; Table S1: Variants of uncertain significance (VUS) identified in the studied cohort of 333 unselected ovarian cancer individuals.
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cancers-10-00442-t001_Table 1

###### 

Clinical, histopathological and molecular data of the ovarian cancer individuals heterozygous for the *BRCA1/2* pathogenic variants.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case No.                              Exon/Intron   Variant in Corresponding cDNA            Predicted Amino Acid Sequence   Variant Type   dbSNP\        ACMG Classification ^2^                                 Age, Years   FIGO Stage   Histology            Family History
                                                                                                                                              ID ^1^                                                                                                               
  ------------------------------------- ------------- ---------------------------------------- ------------------------------- -------------- ------------- ------------------------------------------------------- ------------ ------------ -------------------- ----------------
  M115                                  5             c.181T\>G                                p.(Cys61Gly)                    M              rs28897672    Pathogenic (PS3 + PS4 + PM2 + PP1+ PP5)                 36           IIIC         serous               \-

  M296                                  54            IIIC                                     serous                          \+                                                                                                                                  

  K199                                  46            IIIC                                     serous                          \-                                                                                                                                  

  K221                                  51            IIIC                                     serous                          \-                                                                                                                                  

  D166                                  11            c.676del                                 p.(Cys226Valfs\*8)              F              rs80357941    Pathogenic (PVS1 + PS4 + PM1 + PM2 + PP1 + PP5)         43           ND           serous               \-

  K187                                  11            c.843_846del                             p.(Ser282Tyrfs\*15)             F              rs80357919    Pathogenic (PVS1 + PS4 + PM1 + PM2 + PP1 + PP5)         46           IIIC         serous               \-

  D18                                   11            c.1292dup                                p.(Leu431Phefs\*5)              F              rs80357528    Pathogenic (PVS1 + PS4 + PM1 + PM2 + PP1 + PP5)         42           IIIC         serous               \+

  D138                                  11            c.1687C\>T                               p.(Gln563\*)                    N              rs80356898    Pathogenic (PVS1+PS4+PM1+PM2 + PP1 + PP5)               49           ND           serous               ND

  K100                                  45            IIB                                      serous                          \+                                                                                                                                  

  M397                                  11            c.3296del                                p.(Pro1099Leufs\*10)            F              rs80357815    Pathogenic (PVS1 + PM2 + PM4 + PP5)                     59           IIIC         serous               ND

  D53                                   11            c.3626T\>G                               p.(Leu1209\*)                   N              rs786203884   Pathogenic (PVS1 + PS4 + PM2 + PM4 + PP1 + PP5)         59           ND           low differentiated   ND

  M22                                   11            c.3700_3704del                           p.(Val1234Glnfs\*8)             F              rs80357609    Pathogenic (PVS1 + PM1 + PM2 + PP5)                     61           IIIB         serous               ND

  M38                                   43            IIIC                                     serous                          \-                                                                                                                                  

  M66                                   52            ND                                       serous                          ND                                                                                                                                  

  D3                                    45            IIIC                                     serous                          \+                                                                                                                                  

  D23                                   47            IV                                       serous                          \-                                                                                                                                  

  D63                                   55            IIIC                                     serous                          \+                                                                                                                                  

  D70                                   48            ND                                       serous                          ND                                                                                                                                  

  D71                                   47            ND                                       serous                          \-                                                                                                                                  

  D104                                  56            ND                                       low differentiated              \-                                                                                                                                  

  D136                                  43            IIIB                                     serous                          \-                                                                                                                                  

  D156                                  47            ND                                       serous                          \-                                                                                                                                  

  K65                                   64            IIIC                                     serous                          \+                                                                                                                                  

  K125                                  50            IIIC                                     serous                          \-                                                                                                                                  

  K152                                  66            IV                                       serous                          \+                                                                                                                                  

  K189                                  63            IIIC                                     low differentiated              \+                                                                                                                                  

  K74                                   11            c.3756_3759del                           p.(Ser1253Argfs\*10)            F              rs80357868    Pathogenic (PVS1 + PS4 + PM1 + PM2 + PP1 + PP5)         45           IV           serous               \+

  D15                                   11            c.4035del                                p.(Glu1346Lysfs\*20)            F              rs80357711    Pathogenic (PVS1 + PS4 + PM1 + PM2 + PP1 + PP5)         54           IIB          serous               \-

  K222                                  ND            IIB                                      low differentiated              \+                                                                                                                                  

  M92                                   13            c.4357+2T\>G;\                           p.(Arg1377Tyrfs\*2)             S              rs80358152    Pathogenic (PVS1 + PS2 + PM2 + PP1 + PP3 + PP5)         48           IIIC         serous               \+
                                                      r.\[4186_4357del\];\[=\]                                                                                                                                                                                     

  M95                                   13            45                                       IIIC                            serous         \-                                                                                                                   

  M395                                  14            c.4484+1G\>A; r.\[4358_4484del\];\[=\]   p.(Glu1462\*)                   S              rs80358063    Pathogenic (PVS1 + PS3 + PP1 + PP3 + PP4 + PP5)         41           IIIC         serous               ND

  K201                                  52            IV                                       mesonephroid                    \+                                                                                                                                  

  D140                                  15            c.4675G\>A; r.\[4665_4675del\];\[=\]     p.(Glu1556Glyfs\*13)            S              rs80356988    Pathogenic (PS3 + PM1 + PM2 + PP1 + PP5)                37           IIIC         serous               ND

  K73\                                  15            c.4675+1G\>A; r.\[4485_4675del\];\[=\]   p.(Ser1496Glyfs\*14)            S              rs80358044    Pathogenic (PVS1 + PS3 + PM1 + PM2 + PP1 + PP3 + PP5)   44\          IIIC\        serous\              ND\
  K108                                                                                                                                                                                                              41           IIIC         clear cell           -

  D152                                  16            c.4689C\>G                               p.(Tyr1563\*)                   N              rs80357433    Pathogenic (PVS1 + PS4 + PM1 + PP1 + PP3 + PP4)         38           ND           serous               \-

  D72                                   16            c.4986+6T\>G,\                           p.(Met1663Valfs\*14)            S              rs80358086    Pathogenic (PS3 + PS4 + PM1 + PM2 + PP1 + PP3 + PP5)    47           IIIC         serous               \+
                                                      r.\[4916+1_4916+65ins\];\[=\]                                                                                                                                                                                

  M50                                   20            c.5266dup                                p.(Gln1756Profs\*74)            F              rs397507247   Pathogenic (PVS1 + PM1 + PP5)                           52           IIIC         serous               \+

  M108                                  63            ND                                       serous                          ND                                                                                                                                  

  M138                                  65            ND                                       serous                          \+                                                                                                                                  

  M225                                  50            IIID                                     serous                          \+                                                                                                                                  

  M226                                  51            IIIC                                     serous                          \+                                                                                                                                  

  M227                                  58            IIIC                                     serous                          \-                                                                                                                                  

  M314                                  46            IIIC                                     endometrial                     \+                                                                                                                                  

  M323                                  37            IIIC                                     serous                          \+                                                                                                                                  

  M368                                  60            ND                                       serous                          ND                                                                                                                                  

  M374                                  66            ND                                       serous                          ND                                                                                                                                  

  M378                                  36            ND                                       serous                          ND                                                                                                                                  

  D9                                    43            IIIB                                     endometrial                     \+                                                                                                                                  

  D27                                   66            IIIC                                     serous                          ND                                                                                                                                  

  D66                                   47            ND                                       serous                          \+                                                                                                                                  

  D83                                   50            IIIC                                     serous                          \+                                                                                                                                  

  D99                                   ND            IIIC                                     serous                          ND                                                                                                                                  

  D105                                  50            ND                                       serous                          \+                                                                                                                                  

  D144                                  56            IIC                                      serous                          ND                                                                                                                                  

  D149                                  40            ND                                       serous                          \-                                                                                                                                  

  K53                                   60            IIIC                                     serous                          \+                                                                                                                                  

  K121                                  52            IIIB                                     clear cell                      \-                                                                                                                                  

  K197                                  43            IIIC                                     endometrial                     \-                                                                                                                                  

  ***BRCA2*(NM_000059.3; LRG_293t1)**                                                                                                                                                                                                                              

  M164                                  11            c.2808_2811del                           p.(Ala938Profs\*21)             F              rs80359351    Pathogenic (PVS1 + PS4 + PM2 + PP5)                     81           ND           serous               \+

  D121                                  11            c.3847_3848del                           p.(Val1283Lysfs\*2)             F              rs746229647   Pathogenic (PVS1 + PM1 + PM2 + PP1 + PP5)               ND           ND           serous               ND

  D114                                  11            c.3860del                                p.(Asn1287Ilefs\*6)             F              rs80359406    Pathogenic (PVS1 + PS4 + PM1 + PM2 + PP1 + PP5)         54           IIIC         serous               \+

  M8                                    11            c.3975_3978dup                           p.(Ala1327Cysfs\*4)             F              rs764689249   Pathogenic (PVS1 + PS4 + PM2 + PP5)                     45           IV           serous               \+

  K183                                  56            IV                                       low differentiated              \+                                                                                                                                  

  K212                                  11            c.4440T\>G                               p.(Tyr1480\*)                   N              rs397507719   Pathogenic (PVS1 + PM1 + PM2 + PP1 + PP3 + PP5)         54           IIIC         serous               \+

  M178                                  11            c.5042_5043del                           p.(Val1681Glufs\*7)             F              rs80359478    Pathogenic (PVS1 + PS4 + PM1 + PM2 + PP1 + PP5)         62           IIIC         serous               \-

  D160                                  11            c.5238dup                                p.(Asn1747\*)                   F              rs80359499    Pathogenic (PVS1 + PM1 + PM2 + PP1 + PP5)               51           IIIC         serous               \-

  K172                                  55            IIIC                                     serous                          \-                                                                                                                                  

  K254                                  11            c.5279C\>A                               p.(Ser1760\*)                   N              novel         Pathogenic (PVS1 + PM1 + PM2 + PP1 + PP3 + PP5)         ND           IV           mesonephroid         \-

  K93                                   11            c.6393_6396del                           p.(Lys2131Asnfs\*5)             F              rs397507849   Pathogenic (PVS1 + PM1 + PM2 + PP1 + PP5)               76           IIIC         serous               ND
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^1^ RS number based on the dbSNP Database (<https://www.ncbi.nlm.nih.gov/projects/SNP/>) (as of September 2018); ^2^ Interpretation of variants pathogenicity based on the American the College of Medical Genetics and Genomics (ACMG) recommendations \[[@B15-cancers-10-00442]\], i.e., **PVS1**: null variant (nonsense, frameshift, canonical +/−1 or 2 splice sites, initiation codon, single or multi-exon deletion) in a gene where loss of function (LOF) is a known mechanism of a disease, **PS1**: same amino acid change as a previously established pathogenic variant regardless of nucleotide change, **PS2**: proven de novo (both maternity and paternity confirmed), **PS3**: well-established functional studies, **PS4**: the prevalence of the variant in affected individuals is significantly increased compared to the prevalence in controls, **PM1**: located in a mutational hot spot and/or in critical functional domain, **PM2**: absent from controls, **PM3**: for recessive disorders, detected in *trans* with a pathogenic variant, **PM4**: protein length changes due to in-frame or stop-loss variants, **PM5**: novel missense change at amino acid residue where a different pathogenic missense change has been seen before, **PM6**: assumed de novo, but without confirmation of paternity and maternity, **PP1**: co-segregation with disease in multiple affected family members, **PP2**: missense variant in a gene that has a low rate of benign missense variation, **PP3**: multiple lines of computational evidence support a deleterious effect on the gene or gene product, **PP4**: individual's phenotype or family history is highly specific for a disease, **PP5**: reputable source reports variant as pathogenic. To classify a variant as pathogenic the following criteria need to be fulfilled: ≥ 2 strong (PS1--PS4) OR 1 strong (PS1--PS4) and ≥3 moderate (PM1--PM6) OR 1 strong (PS1--PS4) and 2 moderate (PM1--PM6) and ≥2 supporting (PP1--PP5) OR 1 strong (PS1--PS4) and 1 moderate (PM1--PM6) and ≥4 supporting (PP1-PP5). **Abbreviations**: **FIGO**: International Federation of Gynecology and Obstetrics; **ND**: no data; **F**: frameshift; **N**: nonsense; **S**: splicing; **M**: missense.

cancers-10-00442-t002_Table 2

###### 

Clinical, histopathological and molecular data of the ovarian cancer individuals heterozygous for the pathogenic or likely pathogenic variants in moderate- and low-penetrance genes.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case No.                               Exon/Intron   Variant in Corresponding cDNA            Predicted Amino Acid Sequence   Variant Type   dbSNP\                    ACMG Classification ^2^                     Age,\   FIGO Stage   Histology               Family History   *BRCA1/2*\
                                                                                                                                               ID ^1^                                                                Years                                                         Status
  -------------------------------------- ------------- ---------------------------------------- ------------------------------- -------------- ------------------------- ------------------------------------------- ------- ------------ ----------------------- ---------------- -------------------------
  M33                                    16            c.7927_7928del                           p.(Leu2643Asnfs\*10)            F              novel                     Pathogenic\                                 41      IIIC         serous                  \-               \-
                                                                                                                                                                         (PVS1 + PM1 + PM2)                                                                                        

  ***ATM***(NM_000051.3, LRG_135t1)                                                                                                                                                                                                                                                

  D73                                    41            c.6095G\>A                               p.(Arg2032Lys)                  M              rs139770721               Pathogenic\                                 59      IC           serous/mucinous         \-               \-
                                                                                                                                                                         (PS3 + PM2 + PP3 + PP5)                                                                                   

  ***BLM*(NM_000057.2, LRG_20t1)**                                                                                                                                                                                                                                                 

  M66                                    2             c.98 + 1G\>C                             p.(?)                           S              rs750293380               Pathogenic\                                 52      ND           serous                  \-               *BRCA1*: c.3700_3704del
                                                                                                                                                                         (PVS1 + PM2 + PP3)                                                                                        

  M71                                    7             c.1642C\>T                               p.(Gln548\*)                    N              rs200389141               Pathogenic\                                 61      IIIC         serous                  \-               \-
                                                                                                                                                                         (PVS1 + PP3 + PP5)                                                                                        

  ***BRIP1* (NM_032043.2; LRG_300t1)**                                                                                                                                                                                                                                             

  K190                                   11            c.1510dup                                p.(Ile504Asnfs\*7)              F              rs775735278               Pathogenic\                                 54      IIB          endometrial             \-               \-
                                                                                                                                                                         (PVS1 + PM2 + PP5)                                                                                        

  ***CHEK2*(NM_007194.3)**                                                                                                                                                                                                                                                         

  M140                                   3             c.444 + 1G\>A,\                          p.(Glu149Ilefs\*41)             S              rs121908698               Pathogenic (PVS1 + PS3 + PP3 + PP5)         54      ND           myxoid leiomyosarcoma   ND               \-
                                                       r.\[ = ,444 + 1_444 + 2insATAG\];\[=\]                                                                                                                                                                                      

  M374                                   11            c.1100del                                p.(Thr367Metfs\*15)             F              rs555607708               Pathogenic\                                 66      IIIC         serous                  ND               *BRCA1*: c.5266dup
                                                                                                                                                                         (PVS1 + PS3 + PP3 + PP5)                                                                                  

  D104                                   56            ND                                       low differentiated              \-             *BRCA1*: c.3700_3704del                                                                                                             

  M113                                   11            c.1169A\>C                               p.(Tyr390Ser)                   M              rs200928781               Likely pathogenic (PS3 + PM1 + PP3 + PP5)   27      IIIB         serous                  \-               \-

  ***MRE11A*(NM_005591.3; LRG_85)**                                                                                                                                                                                                                                                

  M42                                    3             c.77T\>C                                 p.(Met26Thr)                    M              rs372068015               Likely pathogenic (PM2 + PM3 + PP1 + PP5)   61      IIB          serous                  \-               \-

  ***NBN* (NM_002485.4; LRG_158t1)**                                                                                                                                                                                                                                               

  K74                                    4             c.373A\>T                                p.(Lys125\*)                    N              novel                     Pathogenic\                                 45      IV           serous                  \+               *BRCA1:* c.3756_3759del
                                                                                                                                                                         (PVS1 + PM2 + PP3)                                                                                        

  K124                                   6             c.643C\>T                                p.(Arg215Trp)                   M              rs34767364                Likely pathogenic\                          47      IIIC         serous                  \-               \-
                                                                                                                                                                         (PS2 + PM1 + PM3)                                                                                         

  M86                                    6             c.657_661del                             p.(Lys219Asnfs\*16)             F              rs587776650               Pathogenic\                                 64      IIIC         serous                  \-               \-
                                                                                                                                                                         (PVS1 + PS3 + PM2 + PP5)                                                                                  

  D131                                   76            ND                                       serous                          ND             \-                                                                                                                                  

  K135                                   55            IIIC                                     serous                          \-             \-                                                                                                                                  

  K208                                   ND            IIIB                                     serous                          \-             \-                                                                                                                                  

  ***PALB2* (NM_024675.3; LRG_308t1)**                                                                                                                                                                                                                                             

  M407                                   5             c.2456_2463del                           p.(Lys819Thrfs\*4)              F              novel                     Pathogenic\                                 53      IIB          serous                  ND               \-
                                                                                                                                                                         (PVS1 + PM2 + PP5)                                                                                        

  K219                                   7             c.2632G\>T                               p.(Glu878\*)                    N              novel                     Pathogenic\                                 54      IIIC         ND                      \-               \-
                                                                                                                                                                         (PVS1 + PM1 + PM2 + PP3 + PP5)                                                                            

  ***RAD50* (NM_005732.3)**                                                                                                                                                                                                                                                        

  M161                                   21            c.3266_3273delinsT                       p.(Lys1089Ilefs\*17)            F              novel                     Pathogenic\                                 46      IA           serous                  \-               \-
                                                                                                                                                                         (PVS1 + PM2 + PP5)                                                                                        

  ***RAD51C*(NM_058216.1; LRG_314t1)**                                                                                                                                                                                                                                             

  K237                                   4             c.706-2A\>G,\                            p.(Arg237_Val280del)            S              rs587780259               Pathogenic\                                 ND      IIC          serous                  \+               \-
                                                       r.\[706_837del\];\[=\]                                                                                            (PVS1 + PM2 + PP3 + PP5)                                                                                  
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^1^ RS number based on the dbSNP Database (<https://www.ncbi.nlm.nih.gov/projects/SNP/>) (as of September 2018); ^2^ Interpretation of variants pathogenicity based on the American the College of Medical Genetics and Genomics (ACMG) recommendations \[[@B15-cancers-10-00442]\], i.e., **PVS1**: null variant (nonsense, frameshift, canonical +/−1 or 2 splice sites, initiation codon, single or multi-exon deletion) in a gene where loss of function (LOF) is a known mechanism of a disease, **PS1**: same amino acid change as a previously established pathogenic variant regardless of nucleotide change, **PS2**: proven de novo (both maternity and paternity confirmed), **PS3**: well-established functional studies, **PS4**: the prevalence of the variant in affected individuals is significantly increased compared to the prevalence in controls, **PM1**: located in a mutational hot spot and/or in critical functional domain, **PM2**: absent from controls, **PM3**: for recessive disorders, detected in *trans* with a pathogenic variant, **PM4**: protein length changes due to in-frame or stop-loss variants, **PM5**: novel missense change at amino acid residue where a different pathogenic missense change has been seen before, **PM6**: assumed de novo, but without confirmation of paternity and maternity, **PP1**: co-segregation with disease in multiple affected family members, **PP2**: missense variant in a gene that has a low rate of benign missense variation, **PP3**: multiple lines of computational evidence support a deleterious effect on the gene or gene product, **PP4**: individual's phenotype or family history is highly specific for a disease, **PP5**: reputable source reports variant as pathogenic. To classify a variant as pathogenic the following criteria need to be fulfilled: ≥2 strong (PS1--PS4) OR 1 strong (PS1--PS4) and ≥3 moderate (PM1--PM6) OR 1 strong (PS1--PS4) and 2 moderate (PM1--PM6) and ≥2 supporting (PP1--PP5) OR 1 strong (PS1--PS4) and 1 moderate (PM1--PM6) and ≥4 supporting (PP1--PP5). **Abbreviations**: **FIGO**: International Federation of Gynecology and Obstetrics; **ND**: no data; **F**: frameshift; **N**: nonsense; **S**: splicing; **M**: missense.
